News
Capricor’s BLA for Deramiocel was granted Priority Review in March 2025 and was supported by data from the HOPE-2 trial, its open-label extension (OLE), and natural history comparisons from FDA-funded ...
Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are ...
20h
Investor's Business Daily on MSNStocks To Watch: Capricor Therapeutics Sees RS Rating Rise To 86Capricor TherapeuticsCAPR just hit that mark, with a jump from 69 to 86 Thursday. Please watch the video at Investors.com - ...
The agency disclosed a tranche of more than 200 complete response letters from the past five years, but only those involving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results